KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $258.0 million.

  • Acadia Pharmaceuticals' Cash & Equivalents rose 66.29% to $258.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.0 million, marking a year-over-year increase of 66.29%. This contributed to the annual value of $319.6 million for FY2024, which is 69.40% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Cash & Equivalents stood at $258.0 million for Q3 2025, which was up 1.72% from $253.6 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Cash & Equivalents registered a high of $319.6 million during Q4 2024, and its lowest value of $94.6 million during Q3 2021.
  • Its 3-year average for Cash & Equivalents is $206.5 million, with a median of $204.7 million in 2024.
  • Over the last 5 years, Acadia Pharmaceuticals' Cash & Equivalents had its largest YoY gain of 75.94% in 2021, and its largest YoY loss of 79.08% in 2021.
  • Over the past 5 years, Acadia Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $147.4 million in 2021, then declined by 22.10% to $114.8 million in 2022, then surged by 64.27% to $188.7 million in 2023, then surged by 69.40% to $319.6 million in 2024, then skyrocketed by 66.29% to $258.0 million in 2025.
  • Its Cash & Equivalents was $258.0 million in Q3 2025, compared to $253.6 million in Q2 2025 and $217.7 million in Q1 2025.